Differential expression of CD10 in prostate cancer and its clinical implication.
Differential expression of CD10 in prostate cancer and its clinical implication.
复制标题
DOI：
10.1186/1471-2490-7-3
复制
发表时间：
2007-03-02
期刊：
影响因子：
2
通讯作者：
Liu AY
中科院分区：
文献类型：
--
作者：
Dall'Era MA;True LD;Siegel AF;Porter MP;Sherertz TM;Liu AY
CD10是一种跨膜金属内肽酶，可切割多种肽生长因子并使其失活。CD10表达缺失是人类前列腺癌常见的早期事件；然而，CD10阳性的癌细胞经常出现在淋巴结转移中。我们假设表达高水平CD10的前列腺肿瘤具有更强的侵袭性生物学，具有早期淋巴结转移倾向。87例患者，53例在根治性前列腺切除术（RP）时患有和34例未患病理性器官局限性前列腺癌，被用于研究。14例在手术时发现淋巴结转移的患者被确定并纳入本研究。从可用的OCT冷冻肿瘤标本中提取一系列切片进行CD10免疫组织化学处理。根据CD10染色的存在和强度对癌腺进行分级，并估计癌腺染色阳性的总体百分比。临床特征包括术前、术后PSA和Gleason评分。用CD13染色进行了类似的研究，作为统计分析的对照。为了统计分析，根据观察到的累积分布的最大分离度，将强染色定义为> 20%阳性。CD10表达与Gleason分级、肿瘤分期及术前血清PSA显著相关。来自淋巴结转移患者的70%的RP标本显示强烈的CD10染色，而整个队列中为30% （OR = 3.4, 95% CI: 1.08-10.75, P = 0.019）。CD10染色增加与RP后PSA复发相关。CD13染色与这些相同的临床参数没有显著相关性。这些结果表明，前列腺癌中CD10的表达对应于一种更具侵袭性的表型，具有更高的恶性潜能，组织学上用Gleason评分来描述。CD10为前列腺癌分层预测肿瘤的生物学行为提供了潜在的临床应用。
CD10 is a transmembrane metallo-endopeptidase that cleaves and inactivates a variety of peptide growth factors. Loss of CD10 expression is a common, early event in human prostate cancer; however, CD10 positive cancer cells frequently appear in lymph node metastasis. We hypothesize that prostate tumors expressing high levels of CD10 have a more aggressive biology with an early propensity towards lymph node metastasis. Eighty-seven patients, 53 with and 34 without pathologically organ confined prostate cancer at the time of radical prostatectomy (RP), were used for the study. Fourteen patients with lymph node metastasis found at the time of surgery were identified and included in this study. Serial sections from available frozen tumor specimens in OCT were processed for CD10 immunohistochemistry. Cancer glands were graded for the presence and intensity of CD10 staining, and overall percentage of glands staining positive was estimated. Clinical characteristics including pre- and post-operative PSA and Gleason score were obtained. A similar study as a control for the statistical analysis was performed with CD13 staining. For statistical analysis, strong staining was defined as > 20% positivity based on the observed maximum separation of the cumulative distributions. CD10 expression significantly correlated with Gleason grade, tumor stage, and with pre-operative serum PSA. Seventy percent of RP specimens from patients with node metastasis showed strong staining for CD10, compared to 30% in the entire cohort (OR = 3.4, 95% CI: 1.08–10.75, P = 0.019). Increased staining for CD10 was associated with PSA recurrence after RP. CD13 staining did not correlate significantly with any of these same clinical parameters. These results suggest that the expression of CD10 by prostate cancer corresponds to a more aggressive phenotype with a higher malignant potential, described histologically by the Gleason score. CD10 offers potential clinical utility for stratifying prostate cancer to predict biological behavior of the tumor.